Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
"Cancer cell oncolysis" describes the process by which cancer cells are destroyed, typically by the rupture (lysis) of their membranes. In the context of modern cancer therapy, it is often discussed with reference to **oncolytic virus therapy**: genetically engineered or naturally occurring viruses are designed to selectively infect and replicate in cancer cells, causing them to burst and die. This primary lytic effect can also stimulate an immune response against the tumor by exposing tumor-specific antigens. Oncolysis is not a specific protein, gene, or receptor, but is an important therapeutic mechanism and endpoint in cancer treatment.
Direct viral lysis of cancer cells\nIndirect activation of the immune response via release of tumor antigens\nAlteration of the tumor microenvironment to facilitate cell death and immune infiltration
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cancer cell oncolysis.